Luteal Support and Intrauterine Insemination (IUI) With Clomiphene Citrate
Information source: Universitair Ziekenhuis Brussel
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Infertility
Intervention: micronized progesterone (Drug)
Phase: N/A
Status: Completed
Sponsored by: Universitair Ziekenhuis Brussel
Summary
The purpose of this study is to assess the effect of luteal phase supplement (LPS) on
pregnancy rate in IUI cycles stimulated with clomiphene citrate.
Clinical Details
Official title: Ovulation Induction With Clomiphene Citrate: to Support or Not to Support the Luteal Phase
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: ongoing pregnancy rate
Secondary outcome: implantation rate,clinical pregnancy rate
Eligibility
Minimum age: 18 Years.
Maximum age: 36 Years.
Gender(s): Female.
Criteria:
Inclusion Criteria:
- Age ≤ 36 years
- Body mass index between 18 and 29
- Presence of both ovaries
- Basal levels of estradiol (≤ 80 pg/ml) and progesterone (≤ 1. 6ng/ml) on day one of
the cycle and a day three FSH level of <12IU/L
- Patients can enter the study only once.
- Only the first IUI attempt will be included ( at the 2nd and 3 rd attempt
progesterone could be administrated if it is necessary but these attempts will be
excluded from the study)
- Normal HSG (maximum 3 months prior starting the stimulation).
- Donor sperm can be included
Exclusion Criteria:
- Polycystic ovarian syndrome (Rotterdam criteria)
- Endometriosis(≥AFS III)
Locations and Contacts
Additional Information
Starting date: September 2008
Last updated: July 1, 2013
|